Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
- GEN-009 neoantigen vaccine advancing to IND filing -
- Balance sheet strengthened with
- Conference call today at
"We've had a productive start to 2018 and are encouraged by both the progress with our lead neoantigen cancer vaccine, GEN-009, and the broader application of our ATLAS™ technology to cancer," said
Recent Milestones & Events
November 2017: At the 32nd Annual Meeting of the Society for Immunotherapy of Cancer(SITC 2017), Genocea presented data demonstrating the power and versatility of its ATLAS platform and its potential superiority to in silico methods of neoantigen identification, as well as data highlighting the discovery of unexpected and novel T cell antigens for vaccines against colorectal cancer and non-small cell lung cancer. January 2018: Genocea announced completion of a $55 millionfinancing, including significant investments by New Enterprise Associates(NEA) and Vivo Capital(Vivo). January 2018: The U.S. Patent and Trademark Officeissued an allowance on United States Patent 9,873,870, further strengthening the company's intellectual property position on its ATLAS platform for the identification and characterization of neoantigens and tumor-associated antigens. January 2018: Genoceaand Oncovir, Inc.entered into a license and supply agreement for Oncovir's Hiltonol® (poly-ICLC) adjuvant, a key component of Genocea's personalized cancer vaccine candidate, GEN-009.
Anticipated Upcoming Milestones & Events
- Q1 2018: The company expects to file an Investigational New Drug (IND) application with the
U.S. Food and Drug Administrationfor its GEN-009 personalized cancer vaccine. March 2018: Genocea management is scheduled to present at the Cowen and Company Annual Health Care Conferencein Boston( March 12-14), and at the Needham & Co.Annual Healthcare Conference in New York City(March 27-28).
- Mid-2018: Genocea plans to initiate a Phase 1/2a clinical trial for GEN-009 in patients with a variety of tumor types. The first part of this trial is expected to enroll 6 patients with no evidence of disease but a high likelihood of relapse. Safety and immunogenicity data will be monitored, with preliminary results expected in the first half of 2019.
Corporate Update and Financial Guidance
Genocea continues to explore strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy to treat the large patient population infected with genital herpes, many of whom are dissatisfied with their current treatment options.
Genocea expects that its existing cash and cash equivalents are sufficient to support its operating expenses and capital expenditure requirements into the second half of 2019 without assuming the expected benefit of the restructuring or refinancing of its debt facility.
Genocea will host a conference call and webcast today at
Fourth Quarter 2017 Financial Results
- Cash Position: As of
December 31, 2017, cash and cash equivalents were $12.3 millioncompared to $22.0 millionas of September 30, 2017.
- Research and Development (R&D) Expenses: R&D expenses decreased approximately
$3.9 millionto $7.9 millionfor the quarter ended December 31, 2017from $11.8 millionfor the same period ended December 31, 2016. The decrease was primarily driven by $6.5 millionin reduced GEN-003 costs, as a result of the strategic shift and restructuring announced in September 2017. Decreases in GEN-003 costs were offset by a $3.9 millionincrease in costs incurred on the Company's GEN-009 program as it continued to develop its supply chain and manufacturing capabilities to prepare for the planned IND filing and initiation of clinical trials for GEN-009.
- General and Administrative (G&A) Expenses: G&A expenses decreased approximately
$1.4 millionto $2.5 millionfor the quarter ended December 31, 2017from $3.9 millionfor the quarter ended December 31, 2016. The decrease was driven by reduced compensation, consulting and professional service costs, depreciation and facility related costs.
- Net Loss: Net loss was
$10.7 millionfor the quarter ended December 31, 2017, compared to a net loss of $16.0 millionfor the same period in 2016.
Full Year 2017 Financial Results
- Cash Position: As of
December 31, 2017, cash and cash equivalents were $12.3 millioncompared to cash, cash equivalents, and investments totaling $63.4 millionas of December 31, 2016.
- R&D Expenses: R&D expenses increased approximately
$4.6 millionto $39.2 millionfor the year ended December 31, 2017from $34.6 millionfor the year ended December 31, 2016. On a program basis, GEN-009 and other immuno-oncology costs increased by $9.5 million, driven primarily by increased headcount, consulting and professional service costs, manufacturing and clinical and lab related costs in anticipation of the expected IND filing for GEN-009 in early 2018. GEN-003 costs increased $1.9 million, driven by increased external manufacturing related expenses, headcount and consulting and professional service costs in advance of the previously planned Phase 3 trials, offset by decreased clinical and lab related costs. Increased spending on these programs was offset by lower costs on other infectious disease programs previously deprioritized in 2016.
- G&A Expenses: General and administrative expense decreased
$2.0 millionto $13.4 millionfor the year ended December 31, 2017from $15.4 millionfor the year ended December 31, 2016. Decreases were driven by lower consulting and professional services costs, facility-related costs and depreciation.
- Restructuring: As a result of the
Company's strategic shift to immuno-oncology, which was announced in
September 2017, restructuring charges of $2.6 millionwere incurred for employee severance, employee benefits, contract terminations and asset impairment. Of these charges, $1.1 millionwere paid through December 31, 2017, $0.5 millionwere recorded as accrued expenses at December 31, 2017and $1.0 millionwere non-cash charges recorded during the year ended December 31, 2017.
- Net Loss: Net loss was
$56.7 millionfor the year ended December 31, 2017, compared to a net loss of $49.6 millionfor the year ended December 31, 2016.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. For more information, please visit www.genocea.com.
Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties that change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Genocea's ability to progress any product candidates in preclinical or clinical trials; the ability of ATLAS to identify promising oncology vaccine and immunotherapy product candidates; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; anticipated preclinical and clinical trial results; anticipated timing for initiation of new preclinical and clinical trials; current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, regulatory authorities may require additional studies for approval and the product may not prove to be safe and efficacious; Genocea's ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; risks associated with the manufacture and supply of clinical and commercial product; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; Genocea's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the rate of cash utilized by Genocea in its business and the period for which existing cash will be able to fund such operation; Genocea's ability to obtain adequate financing in the future to continue its preclinical and clinical programs through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; the availability of qualified personnel and other factors set forth under "Risk Factors" in Genocea's Quarterly Report on Form 10-Q for the quarter ended
|CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)|
|Cash, cash equivalents and investments||$||12,273||$||63,362|
|Debt, current and long-term||$||14,311||$||16,958|
|Accrued expenses and other liabilities||5,711||4,354|
|Stockholders' (deficit) equity||(6,050||)||45,541|
|Total liabilities and stockholders' equity||$||17,488||$||69,896|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)|
|(In thousands, except per share amounts)|
|Three months ended||Twelve months ended|
|Research and development||7,880||11,824||39,204||34,645|
|General and administrative||2,478||3,858||13,433||15,427|
|Refund of research and development expense||—||—||—||(1,592||)|
|Total operating expenses||10,385||15,682||55,255||48,480|
|Loss from operations||(10,385||)||(15,682||)||(55,255||)||(48,245||)|
|Other income and expense:|
|Total other income and expense||(347||)||(352||)||(1,455||)||(1,328||)|
|Net loss per share - basic and diluted||$||(0.37||)||$||(0.56||)||$||(1.98||)||$||(1.75||)|
|Weighted-average number of common shares used in computing net loss per share - basic and diluted||28,705||28,394||28,603||28,299|
News Provided by Acquire Media